February 11, 2019 10:21 AM EST
News Briefing

3SBio inks Chi­na deal with Boston-based Verseau; Er­ic Topol calls for dig­i­tal ed­u­ca­tion in NHS re­port

ENDPOINTS

→ Chi­na’s 3SBio has li­censed rights to three im­muno-on­col­o­gy as­sets dis­cov­ered by Verseau Ther­a­peu­tics. Boston-based Verseau has a plat­form …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times